Head to head
Beta Bionics vs Abbott Laboratories
Side-by-side on the measures that matter, with a plain-English read. Full detail: BBNX · ABT
BBNX
Beta Bionics
17.82-1.44%
1-year price shape — -18% over the period
Quant Rating C · 55/100
vs
ABT
Abbott Laboratories
97.43-1.32%
1-year price shape — -24% over the period
Quant Rating E · 15/100
1-year performance, rebased to 100
Abbott Laboratories edges it on the scoreable measures. Abbott Laboratories pays the highest dividend yield; Abbott Laboratories earns the most per share.
| BBNX | ABT | |
|---|---|---|
| Snapshot | ||
| Sector | Medical Devices | Medical Devices |
| Last price | 17.82 | 97.43 |
| Change today | -1.44% | -1.32% |
| 1-year return | -18.4% | -24.1% |
| Market cap | $801.72M | $168.58B |
| 52-week range | 8.80 – 32.71 | 81.39 – 130.33 |
| Valuation | ||
| P/E (TTM) | -10.99 | 31.53 |
| P/E percentile, own 5-yr range | 43rd | 62nd |
| P/B | 3.13 | 3.30 |
| Dividend yield | 0.00% | 2.50% |
| Profitability & growth | ||
| EPS (TTM) | -1.65 | 3.72 |
| Net profit (TTM) | $-74.23M | $6.44B |
| Revenue (TTM) | $119.01M | $46.59B |
| Revenue growth (YoY) | +37.8% | +13.0% |
| Gross margin | 58.3% | 56.6% |
| Operating margin | -69.8% | 15.8% |
| Net margin | -61.3% | 11.6% |
| Free cash flow (TTM) | $-61.41M | $7.82B |
| Ownership & sentiment | ||
| Institutional ownership | 101.3% | 81.2% |
| Insider activity (12mo) | 20 buy / 30 sell | 36 buy / 12 sell |
| Short interest (% of float) | 23.6% | 1.1% |
| Analyst consensus | 77% buy / 23% hold (13) | 100% buy (14) |
| Analyst price target | $24 (+37%) | $125 (+28%) |
| StockVane view | ||
| StockVane Quant Rating | C (55) | E (15) |
| Company | ||
| Employees | 423 | 115,000 |
| Founded | 2015 | 1888 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.